ArticleBMJ case reports2025
Atypical adult-onset Still's disease that fails to meet Yamaguchi and Fautrel criteria.
Article in BMJ case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease is a rare systemic autoinflammatory condition of unknown aetiology. It is a diagnosis of exclusion based primarily on clinical features and non-specific laboratory findings using either the Yamaguchi or Fautrel criteria. Here, we present a case of atypical adult-onset Still's disease in a young man with twice-daily fevers, night sweats and evanescent rash on his face but not enough features to meet the Yamaguchi or Fautrel criteria after extensive (but unrevealing) infectious, autoimmune and malignancy workups. He responded well to corticosteroid therapy with periodic relapses while transitioning to anti-IL1 therapy for 8 months. At a 2-year follow-up, he now remains symptom-free after stopping anti-IL1 therapy for over a year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.